Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally through wholesalers, selected regional wholesalers, and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, EPA. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin 2, Ireland.

Market Cap	$318.10M	P/E Ratio	N/A
52W High	$20.90	52W Low	$11.65
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	-100.0%	52W Position	45.0%
Overall Score	62	Value Score	60
Quality Score	52	Technical Score	75

EPS Current Est	$-1.14	EPS Next Est	$-0.89
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	AMRN	$15.81	-1.37%	165.79K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	AMRN	$15.81	-1.4%	165.79K
3
4
5
6

AMRN

AMRN

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Amarin Corporation plc Data in Excel

Get Amarin Corporation plc Data in Excel